News

Thu, 22/06/2017
CSF diagnostics in neurodegenerative diseases
Munich. Prof. Markus Otto from the Department of Neurology Ulm is invited speaker at the neurocolloquium Munich. Prof. Otto is head of the scientific working group on neurochemistry and neurodegeneration at Ulm University and expert on neurochemical diagnosis of neurodegenerative disease (14-3-3, Tau-protein, Abeta-Peptides, S-100B, H-FABP, alpha synuclein) as well as head of a sample […]...more
Wed, 07/06/2017
Mechanisms of neural stem cell homeostasis in human brain organoids
Mainz. Dr. Jay Gopalakrishnan from the University of Cologne is an emerging leader in the field of brain development and microcephaly. He has been invited by SFB scientist Prof. Rajalingam as guest at the joint MSU/FTN seminar and will present his work in a lecture on “Mechanisms of neural stem cell homeostasis in human brain […]...more
Mon, 29/05/2017
International Symposium “Cells in Motion: Pattern formation in space and time”
Muenster. For the second time, the Cluster of Excellence “Cells in Motion” (CiM) hosts an international symposium. In interdisciplinary sessions and talks, international top class scientists will present their current research questions and findings. The list of speakers comprises experts from chemistry, mathematics, physics, biology and medicine, going beyond the boundaries of specialized fields and […]...more


Wed, 17/05/2017 | Lecture: MS: Can we develop therapies?

Muenster. The Department of Neurology is happy to announce that Dr. Susan Goelz will give a lecture as part of the Neurological Seminar.

Time: Wednesday, May 17, 6:15pm
Place: Large conference room, Level 05 West in the central clinics building, Albert-Schweitzer-Campus 1, 48149 Muenster

Title of her talk: „Putative pathways leading to neurodegeneration in MS:  Can we develop therapies?”

After her time as a Postdoc, Susan Goelz was working as a scientist and manager in the pharmaceutical industry, first at Biogen (from 1988 on), then at Elan Pharmaceuticals. In her time at Biogen, she was responsible for the development and market introduction / approval process of Interferon-beta (Avonex), which has been one of the most successful MS therapies since its FDA approval in 1995. In addition to her post as a lecturer at Oregon Health and Sciences University, she works as a consultant for pharmaceutical companies and specializes in translational medicine, as well as networking between academia and pharmaceutical industries. She has connections all over the world and expertise in the newest techniques, disease models, and treatment options.